Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin E Greer

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Cancer|August 5, 2011
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 studyKathryn F McGonigle, Howard G Muntz, Jacqueline Vuky, et al.
Gynecologic Oncology|March 11, 2009
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group StudyJohn Farley, Sartoru Fuchiuji, Kathleen M Darcy, et al.
Gynecologic Oncology|December 11, 2012
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, Robert A Burger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyRobert F Ozols, Brian N Bundy, Benjamin E Greer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyRobert F Ozols, Brian N Bundy, Benjamin E Greer, et al.
Gynecologic Oncology|September 24, 2004
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group studyRobert S Lavey, P Y Liu, Benjamin E Greer, et al.
Gynecologic Oncology|July 26, 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer, Brian N Bundy, Robert F Ozols, et al.
Gynecologic Oncology|July 29, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyJames S Ferriss, James J Java, Michael A Bookman, et al.
Gynecologic Oncology|September 28, 2010
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han, Robert A Burger, Kathleen M Darcy, et al.
The New England Journal of Medicine|December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancerRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Cancer|August 5, 2011
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 studyKathryn F McGonigle, Howard G Muntz, Jacqueline Vuky, et al.
Gynecologic Oncology|March 11, 2009
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group StudyJohn Farley, Sartoru Fuchiuji, Kathleen M Darcy, et al.
Gynecologic Oncology|December 11, 2012
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, Robert A Burger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyRobert F Ozols, Brian N Bundy, Benjamin E Greer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyRobert F Ozols, Brian N Bundy, Benjamin E Greer, et al.
Gynecologic Oncology|September 24, 2004
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group studyRobert S Lavey, P Y Liu, Benjamin E Greer, et al.
Gynecologic Oncology|July 26, 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer, Brian N Bundy, Robert F Ozols, et al.
Gynecologic Oncology|July 29, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyJames S Ferriss, James J Java, Michael A Bookman, et al.
Gynecologic Oncology|September 28, 2010
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han, Robert A Burger, Kathleen M Darcy, et al.
The New England Journal of Medicine|December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancerRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Pageof 4